# Alternative polyadenylation in Right Ventricular Fibrosis

> **NIH NIH R56** · METHODIST HOSPITAL RESEARCH INSTITUTE · 2024 · $760,708

## Abstract

Project Summary:
Pulmonary hypertension (PH) is a cardiovascular disorder characterized by high mortality, primarily due to right
ventricular (RV) failure (RVF) caused by increased pulmonary vascular resistance. RV fibrosis, a hallmark of
decompensated RVF, lacks targeted therapies, highlighting the need to elucidate the molecular mechanisms
underlying RV fibrosis and dysfunction.
Our research focuses on the role of alternative polyadenylation (APA), a process associated with excessive
production of extracellular matrix (ECM) proteins, in RV fibrosis. APA shortens the 3' untranslated region (UTR)
of transcripts, leading to loss of microRNA binding sites and increased transcript stability. We have identified
Cleavage and Polyadenylation Specific Factor 6 (CPSF6), a key regulator of APA, as being involved in end-
stage RVF. In RVF patients, CPSF6 exhibits lengthened 3' UTR and decreased protein expression. Silencing
CPSF6 in cardiac fibroblasts (CFs) results in 3' UTR shortening and upregulation of major fibrotic mediators,
including TGF-β1 and its receptor, TGFβR1. Pathway analysis further supports 3' UTR shortening in mRNAs
encoding ECM proteins in CPSF6 knockdown CFs. Additionally, we have discovered the role of 4-hydroxy-2-
nonenal (4HNE), a reactive aldehyde generated during oxidative stress, in RVF. Increased 4HNE downregulates
CPSF6, inducing 3' UTR shortening in profibrotic genes and promoting RV fibrosis. The proposed research aims
to investigate these mechanisms and identify therapeutic targets for mitigating RV fibrosis. Our hypothesis posits
that CPSF6 depletion shortens the 3' UTRs of ECM genes, causing their escape from regulation, promoting their
expression, and leading to RV fibrosis. Specifically, we will: Investigate the impact of CPSF6 loss on the 3' UTR
landscape and profibrotic gene expression in RVF (Specific Aim 1). Uncover the mechanism underlying CPSF6
reduction-dependent 3' UTR shortening in CFs and its functional consequences in RVF (Specific Aim 2). Assess
the impact of ALDH2 restoration on alleviating RV fibrosis through CPSF6 regulation (Specific Aim 3).
The validation of our hypotheses and the completion of these aims will highlight the importance of 3' UTR
shortening in ECM deposition and fibrosis in RVF, potentially guiding the development of therapeutic
interventions. Given the limited treatment options and severe consequences of PH, our research holds significant
promise for improving public health.

## Key facts

- **NIH application ID:** 11192961
- **Project number:** 1R56HL169445-01A1
- **Recipient organization:** METHODIST HOSPITAL RESEARCH INSTITUTE
- **Principal Investigator:** RAJARAJAN AMIRTHALINGAM THANDAVARAYAN
- **Activity code:** R56 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $760,708
- **Award type:** 1
- **Project period:** 2024-09-25 → 2026-09-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11192961

## Citation

> US National Institutes of Health, RePORTER application 11192961, Alternative polyadenylation in Right Ventricular Fibrosis (1R56HL169445-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11192961. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*